Drugs / Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02531841 Comparator | Jul 2014 → Nov 2017 | diffuse large B-cell lymphoma | University Hospital Freiburg | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arm A (Fortecortin-ETOPOPHOS-IFO-cell-CARBO-cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02531841 ↗ |
| Known as | AraC | “Chemotherapy included three steps: three cycles of methotrexate (8 g/m2); cytarabine (AraC; two doses of 3 g/m2) and thiotepa (40 mg/m2) followed by stem-cell harvest; HDT with...” PMID 16864853 ↗ Jul 2006 |
| Route | Intravenous | “Cytarabine 2 x 2 g/m²/d i.v. (d2-3)” NCT02531841 ↗ |